The application of genetics and genomics to cancer prevention.

abstract：:Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

journal_title：Seminars in oncology

authors： Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

更新日期：2017-02-01 00:00:00

abstract：:Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

journal_title：Seminars in oncology

authors： Munshi NC,Wilson C

更新日期：2001-12-01 00:00:00

abstract：:The use of adjuvant radiation therapy and chemotherapy diminishes the likelihood of local-regional and distant recurrences and appears to prolong survival in patients who have undergone a complete surgical resection of a Dukes-Kirklin stage B2 or C rectal cancer. Patients with this malignant condition rarely develop p...

journal_title：Seminars in oncology

authors： Mayer RJ

更新日期：1985-09-01 00:00:00

abstract：:We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. Patients who did not require therapy for more than 1 year (n = 54) could be distinguis...

journal_title：Seminars in oncology

authors： Dhodapkar MV,Jacobson JL,Gertz MA,Crowley JJ,Barlogie B

更新日期：2003-04-01 00:00:00

abstract：:To address the urgent need for novel therapies for multiple myeloma (MM), long-term research efforts have characterized the mechanisms whereby MM cells home to the bone marrow and adhere to bone marrow stromal cells and extracellular matrix proteins. Research also characterizes the functional sequelae of this binding ...

journal_title：Seminars in oncology

authors： Anderson KC

更新日期：2002-12-01 00:00:00

abstract：:Preliminary clinical studies demonstrated that 5' nor-anhydro-vinblastine, Navelbine (NVB) has a broader antitumor activity and fewer neurotoxic effects than vinblastine or vincristine. The tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation were used to analyze and compare the effe...

journal_title：Seminars in oncology

authors： Binet S,Fellous A,Lataste H,Krikorian A,Couzinier JP,Meininger V

更新日期：1989-04-01 00:00:00

abstract：:Lung cancer represents the leading cause of cancer mortality worldwide. Its incidence has declined in men but is increasing in women, assuring that this largely preventable disease will continue to affect millions. In small cell lung cancer, the advent of chemotherapy in the 1970s and continued refinements in the 1980...

journal_title：Seminars in oncology

authors： Splinter TA

更新日期：1997-08-01 00:00:00

abstract：:Because etoposide is a cell-cycle phase-specific drug, its degree of cytotoxicity likely relies on duration of cell exposure to a specific concentration. We investigated the maximum tolerated duration of oral etoposide treatment at doses of 100, 75, and 50 mg/d in previously treated patients with biopsy-proven, advanc...

journal_title：Seminars in oncology

authors： Splinter TA,van der Gaast A,Kok TC

更新日期：1992-12-01 00:00:00

abstract：:Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The drug's nonhematologic toxicities are usually mild; its dose-limiting toxicity is neutropenia. Vinorelbine has been studied in many phas...

journal_title：Seminars in oncology

authors： Wozniak AJ

更新日期：1999-10-01 00:00:00

abstract：:Developments in the treatment of extensive small cell lung cancer have proven effective in palliative management but have not yielded improvements in the cure rate for this disease. Strategies involving dose escalation of chemotherapy, including de novo and late intensification dose escalation and dose escalation with...

journal_title：Seminars in oncology

authors： Comis RL

更新日期：1992-12-01 00:00:00

abstract：:Approximately 25% of all lung cancer cases diagnosed in 1993 were due to small cell lung cancer (SCLC). Approximately one third of all SCLC patients present with limited disease. Efforts to improve treatment results for patients with limited-stage SCLC include two recent meta-analyses of combined-modality treatment in...

journal_title：Seminars in oncology

authors： Sandler AB

更新日期：1998-02-01 00:00:00

abstract：:Since its introduction, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antitumor activity in epidermoid carcinomas and adenocarcinomas originating in the esophagus. Paclitaxel is the most active single agent available to treat metastatic esophageal cancer. Combinations of ...

journal_title：Seminars in oncology

authors： Weiner LM

更新日期：1999-02-01 00:00:00

abstract：:Platinum compounds have long played a role in the treatment of gynecologic cancers. Single-agent cisplatin and carboplatin have shown activity in endometrial cancer, and more recent studies have begun to investigate a variety of new platinum-based combinations. In cervical cancer, chemotherapy is used primarily to tre...

journal_title：Seminars in oncology

authors： Muggia FM

更新日期：2004-12-01 00:00:00

abstract：:Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers. Notably, RT causes irreparable damage to salivary glands that increases the risk for severe and long-term oral and pharyngeal disorders. Several strategies in the treatment of head and neck cancers h...

journal_title：Seminars in oncology

authors： Ship JA,Hu K

更新日期：2004-12-01 00:00:00

abstract：:Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial ...

journal_title：Seminars in oncology

authors： Dizon DS,Kemeny NE

更新日期：2002-04-01 00:00:00

abstract：:There are several treatment options for patients with metastatic colorectal cancer (mCRC), including those with disease that has progressed after treatment with chemotherapy. Bevacizumab-containing regimens show good efficacy in patients with previously treated disease. Compared with infused 5-fluorouracil, leucovorin...

journal_title：Seminars in oncology

authors： Giantonio BJ

更新日期：2006-10-01 00:00:00

abstract：:Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

journal_title：Seminars in oncology

authors： Sherer R

更新日期：1998-04-01 00:00:00

abstract：:Targeted therapy for breast cancer has existed since 1986, when Beatson published his observations on oophorectomy. In the past 5 years monoclonal antibodies and tyrosine kinase inhibitors have been evaluated in phase I and II clinical trials of breast cancer. Trastuzumab (Herceptin; Genentech, Inc, South San Francisc...

journal_title：Seminars in oncology

authors： Kaklamani V,O'Regan RM

更新日期：2004-04-01 00:00:00

abstract：:Colorectal cancer is the third most common cause of cancer-related death in both men and women. Surgery is the primary form of treatment, with greater than 90% of patients surviving 5 years or more. The remaining patients have metastatic disease, for which treatment options are limited. The fluoropyrimidine, 5-fluorou...

journal_title：Seminars in oncology

authors： Creemers GJ

更新日期：1997-12-01 00:00:00

abstract：:Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled ...

journal_title：Seminars in oncology

authors： Wu PK,Park JI

更新日期：2015-12-01 00:00:00

abstract：:In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

journal_title：Seminars in oncology

authors： Chmura SJ,Milano MT,Haraf DJ

更新日期：2004-12-01 00:00:00

abstract：:Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

journal_title：Seminars in oncology

authors： Wingard JR

更新日期：1993-10-01 00:00:00

abstract：:Predicting which patients with primary melanoma are at risk of developing metastastic disease is important for making rational therapeutic decisions. Tumor thickness alone is the most commonly used predictor of survival, but other clinical and pathologic variables also play an important role. We have developed two mul...

journal_title：Seminars in oncology

authors： Halpern AC,Schuchter LM

更新日期：1997-02-01 00:00:00

abstract：:Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

journal_title：Seminars in oncology

authors： Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

更新日期：1990-02-01 00:00:00

abstract：:Myeloid neoplasms are characterized by acquired somatic mutations and epigenetic alterations in genes that are crucial for hematopoietic differentiation and cellular proliferation and survival pathways. The heterogeneity and genetic complexity of these disorders is daunting, but the improvement in our knowledge of the...

journal_title：Seminars in oncology

authors： Odenike O,Thirman MJ,Artz AS,Godley LA,Larson RA,Stock W

更新日期：2011-04-01 00:00:00

abstract：:Transport of folates and antifolates in most cells is mediated by the reduced folate carrier (RFCI), an anion exchanging concentrative process, which is opposed by independent exit pump(s) that are directly coupled to energy metabolism. The balance of these processes governs the free intracellular folate level that is...

journal_title：Seminars in oncology

authors： Sierra EE,Goldman ID

更新日期：1999-04-01 00:00:00

abstract：:Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lym...

journal_title：Seminars in oncology

authors： Cheson BD

更新日期：1992-12-01 00:00:00

abstract：:Preclinical models in vitro and in vivo have shown that tumor hypoxia alters the malignant cell phenotype, selecting for p53 mutations, stimulating angiogenesis and metastasis, and markedly reducing the efficacy of both radiotherapy and chemotherapy. Similarly, clinical studies measuring pretreatment tumor oxygen stat...

journal_title：Seminars in oncology

authors： Gandara DR,Lara PN Jr,Goldberg Z,Le QT,Mack PC,Lau DH,Gumerlock PH

更新日期：2002-02-01 00:00:00

abstract：:90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients wit...

journal_title：Seminars in oncology

authors： Gordon LI

更新日期：2003-12-01 00:00:00

abstract：:Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated. In response to these limitations, other single agents have been studied, and a number have demonstr...

journal_title：Seminars in oncology

authors： Roth BJ

更新日期：1996-06-01 00:00:00